Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sonoma Pharmaceuticals, Inc. engages in the development and production of hypochlorous acid (HOCl) products for wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

The shares of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased over 95% pre-market. This is why it happened.

Sonoma Pharmaceuticals Shares Increase Over 95% Pre-Market: Why It Happened

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has launched two new dental products. OroGenix Oral Hygiene Rinse is Sonoma's second dental product in the U.S., and was developed with its

Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and, nasal care, disinfectant use and dermatological conditions today announced financial results for its first fiscal quarter ended June 30, 2021. “This quarter marks the transition from having a dedicated dermatology sales force for our prescription produc

Sonoma Pharmaceuticals Reports First Quarter 2022 Financial Results

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) shares are trading lower by 18.6% at $6.25 after the company reported fourth-quarter EPS and sales results were down year-over-year. Sonoma Pharmaceuticals reported quarterly losses of $1.64 per share.

Why Sonoma Pharmaceuticals Shares Are Getting Hammered Today

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care and dermatological conditions today announced financial results for fiscal year 2021 and the fourth quarter ended March 31, 2021. “For the past 18 months we have been restructuring the Company to cut losses while positioning it for growth,” sa

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2021 Financial Results

Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has entered into an agreement with EMC Pharma LLC for the exclusive right to manage, market, and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the U.S. for an initial term of five years, subject to extension. EMC Pharma will also have a non-exclusive agreement to manage, market, and distribute certain Microcyn-based wound care products into government channels.

Sonoma Pharma Stock Is Trading Higher After Distribution Pact With EMC Pharma

The stock price of Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) increased by over 20% pre-market. This is why it happened.

SNOA Stock Price Increased Over 20% Pre-Market: Why It Happened

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has entered into an agreement with EMC Pharma, LLC for the exclusive right to manage, market and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the United Sta

Sonoma Pharmaceuticals and EMC Pharma Announce an Exclusive Partnership to Expand Commercial Channels of the Microcyn®-based Rx Dermatology and Eye Care Products Nationwide

NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) on behalf of Sonoma stockholders. Our investigation concerns whether Sonoma has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Sonoma filed an 8-K with the SEC on November 17, 2020. The filing announced that the Comp

SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sonoma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the following upcoming virtual conferences.   Event   H.C. Wainwright Global Life Sciences Conference Date   March 9-10, 2021

Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences

New York, New York--(Newsfile Corp. - February 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Sonoma securities you may be entitled to compensation without payment of any out of pocket fees or costs through...

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - SNOA

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its third fiscal quarter and nine months ended December 31, 2020. “We continue to effectively execute our business plan of increasing revenue while reducing our expense

Sonoma Pharmaceuticals Reports Third Quarter FY 2021 Financial Results

NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.

BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA

Los Angeles, California--(Newsfile Corp. - February 8, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or "the Company") (NASDAQ: SNOA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sonoma filed an 8-K with the SEC on November 17, 2020....

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or "the Company") (NASDAQ: SNOA) for violations of the securities laws....

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, disinfectant use and dermatological conditions, and Microderm Technologies Ltd. announce that Dermodacyn® disinfectant has received import clearance as a medical device for Thailand with the help from Microderm's partner VetSynova Co.

Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand

NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially...

ROSEN, GLOBAL INVESTOR COUNSEL, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation is available for on

Sonoma Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma's “unaudited condensed consolidate

ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA

NEW YORK, Dec. 19, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA).   Such investors are advised to contact Robert S. Willoughby at   newaction@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA

Dare Bioscience

Medicenna Therapeutics Corp

Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday after the company announced a partnership with Gabriel Science for dental markets. Sonoma is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions.

Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets.

Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets

Sonoma Pharmaceuticals (SNOA) is in the news Friday after announcing a deal with Crown Laboratories that has SNOA stock on the rise. The post Sonoma Pharmaceuticals News Alert: Why SNOA Stock Is Rocketing Higher Today appeared first on InvestorPlace.

Sonoma Pharmaceuticals News Alert: Why SNOA Stock Is Rocketing Higher Today

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn® Technology-based anti-itch OTC products.

Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

News for Sonoma Pharmaceuticals Stock (SNOA)